Absence of γ-Interferon–inducible Lysosomal Thiol Reductase in Melanomas Disrupts T Cell Recognition of Select Immunodominant Epitopes

Long-lasting tumor immunity requires functional mobilization of CD8+ and CD4+ T lymphocytes. CD4+ T cell activation is enhanced by presentation of shed tumor antigens by professional antigen-presenting cells (APCs), coupled with display of similar antigenic epitopes by major histocompatibility complex class II on malignant cells. APCs readily processed and presented several self-antigens, yet T cell responses to these proteins were absent or reduced in the context of class II+ melanomas. T cell recognition of select exogenous and endogenous epitopes was dependent on tumor cell expression of γ-interferon–inducible lysosomal thiol reductase (GILT). The absence of GILT in melanomas altered antigen processing and the hierarchy of immunodominant epitope presentation. Mass spectral analysis also revealed GILT's ability to reduce cysteinylated epitopes. Such disparities in the profile of antigenic epitopes displayed by tumors and bystander APCs may contribute to tumor cell survival in the face of immunological defenses.

[1]  Richard A. Flavell,et al.  Defective Antigen Processing in GILT-Free Mice , 2001, Science.

[2]  V. Brusic,et al.  gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells , 2001, British Journal of Cancer.

[3]  J. Blum,et al.  Cysteinylation of MHC Class II Ligands: Peptide Endocytosis and Reduction Within APC Influences T Cell Recognition1 , 2001, The Journal of Immunology.

[4]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[5]  C. Nelson,et al.  Structural and Functional Consequences of Altering a Peptide MHC Anchor Residue1 , 2001, The Journal of Immunology.

[6]  R. Dwek,et al.  Folding and Maturation of Tyrosinase-related Protein-1 Are Regulated by the Post-translational Formation of Disulfide Bonds and by N-Glycan Processing* , 2000, The Journal of Biological Chemistry.

[7]  A. van Elsas,et al.  Costimulatory wars: the tumor menace. , 2000, Current opinion in immunology.

[8]  V Brusic,et al.  NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. , 2000, Cancer research.

[9]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[10]  P. Cresswell,et al.  Gamma-interferon-inducible lysosomal thiol reductase (GILT). Maturation, activity, and mechanism of action. , 2000, The Journal of biological chemistry.

[11]  P. Cresswell,et al.  Gamma-Interferon-inducibleLysosomal Thiol Reductase (GILT) , 2000, The Journal of Biological Chemistry.

[12]  J. Blum,et al.  Endocytic Recycling is Required for the Presentation of an Exogenous Peptide via MHC Class II Molecules , 2000, Traffic.

[13]  E. Sercarz,et al.  Cutting Edge: Introduction of an Endopeptidase Cleavage Motif into a Determinant Flanking Region of Hen Egg Lysozyme Results in Enhanced T Cell Determinant Display1 , 2000, The Journal of Immunology.

[14]  Stork Wj,et al.  Melanoma antigens recognised by CD8+ and CD4+ T cells. , 2000 .

[15]  M. Brady,et al.  Restoration of Alloreactivity of Melanoma by Transduction With B7.1 , 2000, Journal of immunotherapy.

[16]  C. Watts,et al.  Antigen Traffic Pathways in Dendritic Cells , 2000, Traffic.

[17]  P. Cresswell,et al.  Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  V. Brusic,et al.  Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells , 2000 .

[19]  J. Kirkwood,et al.  Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading , 2000, Immunological investigations.

[20]  D. Zaller,et al.  Role of APC in the selection of immunodominant T cell epitopes. , 1999, Journal of immunology.

[21]  J. Yewdell,et al.  Modification of Cysteine Residues In Vitro and In Vivo Affects the Immunogenicity and Antigenicity of Major Histocompatibility Complex Class I–restricted Viral Determinants , 1999, The Journal of experimental medicine.

[22]  Ferry Ossendorp,et al.  CD4 T Cells and Their Role in Antitumor Immune Responses , 1999, The Journal of experimental medicine.

[23]  Matteo Bellone,et al.  Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.

[24]  Parkhurst,et al.  Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. , 1999, Journal of immunology.

[25]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[26]  J. Shabanowitz,et al.  Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. , 1998, Journal of immunology.

[27]  P. Hersey,et al.  Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3γ* , 1997, The Journal of Biological Chemistry.

[28]  W. Heath,et al.  Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.

[29]  J. Ting,et al.  Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Leclerc,et al.  Parameters affecting the immunogenicity of recombinant T cell epitopes inserted into hybrid proteins. , 1997, Human immunology.

[31]  N. Leister,et al.  The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. , 1997, Journal of immunological methods.

[32]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[33]  J. Bryant,et al.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.

[34]  A Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.

[35]  S. H. van der Burg,et al.  Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.

[36]  J. Becker,et al.  Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. , 1993, International immunology.

[37]  G. Winter,et al.  Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.

[38]  E. Unanue,et al.  Reduction of disulfide bonds within lysosomes is a key step in antigen processing. , 1991, Journal of immunology.

[39]  P. Jensen Reduction of disulfide bonds during antigen processing: evidence from a thiol-dependent insulin determinant , 1991, The Journal of experimental medicine.

[40]  J. Hansen,et al.  Structural requirements for recognition of the HLA-Dw14 class II epitope: a key HLA determinant associated with rheumatoid arthritis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Guerry,et al.  Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease. , 1989, Journal of immunology.

[42]  N. Shastri,et al.  The choice between two distinct T cell determinants within a 23-amino acid region of lysozyme depends on their structural context. , 1986, Journal of immunology.

[43]  N. Shastri,et al.  Amino acid residues distinct from the determinant region can profoundly affect activation of T cell clones by related antigens. , 1986, Journal of immunology.

[44]  A. Lazaris,et al.  Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma , 2004, Virchows Archiv.

[45]  V. Brusic,et al.  Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  C. Watts,et al.  Capture and processing of exogenous antigens for presentation on MHC molecules. , 1997, Annual review of immunology.

[47]  A. Miller,et al.  Dominance and crypticity of T cell antigenic determinants. , 1993, Annual review of immunology.

[48]  T. Kageshita,et al.  [Expression of HLA-class II antigens in malignant melanoma]. , 1990, Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology.